| Preface |
| List of Contributors |
| DNA-based Nanomaterials / I： |
| Self-assembled DNA Nanotubes / Thom LaBean ; Sung Ha Park1： |
| Introduction / 1.1： |
| DNA Nanotubes Self-assembled from DX Tiles / 1.2： |
| 3DAE-E DX Tile Nanotubes / 1.3： |
| DAE-O DX Tile Nanotubes / 1.4： |
| TX Tile Nanotubes / 1.5： |
| 4 x 4 Tile Nanotubes / 1.6： |
| 6HB Tile Nanotubes / 1.7： |
| Applications / 1.8： |
| Summary and Perspectives / 1.9： |
| References |
| Nucleic Acid Nanoparticles / Guy Zuber ; Benedicte Pons ; Andrew W. Fraley2： |
| The Chemical and Physical Properties of Therapeutic DNA / 2.1： |
| Preparation of Nucleic Acid Nanoparticles: Synthesis and Characterization / 2.3： |
| Rationale / 2.3.1： |
| Synthesis, Characterization and Optimization of Surfactants / 2.3.2： |
| Organization of the Surfactant-DNA Complexes / 2.3.3： |
| Quantification of the Stability of Surfactant-DNA Complexes / 2.3.4： |
| DNA Functionalization for Cell Recognition and Internalization / 2.4： |
| Strategies for Functionalization / 2.4.1： |
| Intercalation / 2.4.2： |
| Triple Helix Formation with Oligodeoxyribonucleotides / 2.4.3： |
| Peptide Nucleic Acids (PNAs) / 2.4.4： |
| Interactions of DNA with Fusion Proteins / 2.4.5： |
| Agents that Bind to the Minor Groove / 2.4.6： |
| DNA Nanoparticles: Sophistication for Cell Recognition and Internalization / 2.5： |
| Preparation of DNA Nanoparticles Enveloped with a Protective Coat and Cell Internalization Elements / 2.5.1： |
| Biomedical Application: Cell Targeting and Internalization Properties of Folate-PEG-coated Nanoparticles / 2.5.2： |
| Concluding Remarks / 2.6： |
| Lipoplexes / Sarah Weisman3： |
| DNA Lipoplexes / 3.1： |
| Composition / 3.2.1： |
| Nanostructure and Microstructure / 3.2.2： |
| Equilibrium Morphology / 3.2.2.1： |
| Nonequilibrium Morphology / 3.2.2.2： |
| Lipoplex Size / 3.2.2.3： |
| Lipofection Efficiency / 3.2.3： |
| In Vitro / 3.2.3.1： |
| In Vivo / 3.2.3.2： |
| ODN Lipoplexes / 3.3： |
| siRNA Lipoplexes / 3.4： |
| Acknowledgments |
| DNA-Chitosan Nanoparticles for Gene Therapy: Current Knowledge and Future Trends / Julio C. Fernandes ; Marcio Jose Tiera ; Francoise M. Winnik4： |
| Chitosan as a Carrier for Gene Therapy / 4.1： |
| Chitosan Chemistry / 4.2.1： |
| General Strategies for Chitosan Modification / 4.2.2： |
| Chitosan-DNA interactions: Transfection Efficacy of Unmodified Chitosan / 4.2.3： |
| Modified Chitosans: Strategies to Improve the Transfection Efficacy / 4.3： |
| The Effects of Charge Density/Solubility and Degree of Acetylation / 4.3.1： |
| Improving the Physicochemical Characteristics of the Nanoparticulate Systems: Solubility, Aggregation and RES Uptake / 4.3.2： |
| Targeting Mediated by Cell Surface Receptors / 4.3.3： |
| Hydrophobic Modification: Protecting the DNA and Improving the Internalization Process / 4.3.4： |
| Methods of Preparation of Chitosan Nanoparticles / 4.4： |
| Complex Coacervation / 4.4.1： |
| Crosslinking Methods / 4.4.2： |
| Chemical Crosslinking / 4.4.2.1： |
| Ionic Crosslinking or Ionic Gelation / 4.4.2.2： |
| Emulsion Crosslinking / 4.4.2.3： |
| Spray Drying / 4.4.2.4： |
| Other Methods / 4.4.2.5： |
| DNA Loading into Nano- and Microparticles of Chitosan / 4.5： |
| DNA Release and Release Kinetics / 4.6： |
| Preclinical Evidence of Chitosan-DNA Complex Efficacy / 4.7： |
| Potential Clinical Applications of Chitosan-DNA in Gene Therapy / 4.8： |
| Conclusion / 4.9： |
| Protein & Peptide-based Nanomaterials / II： |
| Plant Protein-based Nanoparticles / Anne-Marie Orecchioni ; Cecile Duclairoir ; Juan Manuel Irache ; Evelyne Nakache5： |
| Description of Plant Proteins / 5.1： |
| Pea Seed Proteins / 5.2.1： |
| Wheat Proteins / 5.2.2： |
| Preparation of Protein Nanoparticles / 5.3： |
| Preparation of Legumin and Vicilin Nanoparticles / 5.3.1： |
| Preparation of Gliadin Nanoparticles / 5.3.2： |
| Drug Encapsulation in Plant Protein Nanoparticles / 5.4： |
| RA Encapsulation in Gliadin Nanoparticles / 5.4.1： |
| VE Encapsulation in Gliadin Nanoparticles / 5.4.2： |
| Lipophilic, Hydrophilic or Amphiphilic Drug Encapsulation / 5.4.3： |
| Preparation of Ligand-Gliadin Nanoparticle Conjugates / 5.5： |
| Bioadhesive Properties of Gliadin Nanoparticles / 5.6： |
| Ex Vivo Studies with Gastrointestinal Mucosal Segments / 5.6.1： |
| In Vivo Studies with Laboratory Animals / 5.6.2： |
| Future Perspectives / 5.7： |
| Size Optimization / 5.7.1： |
| Immunization in Animals / 5.7.2： |
| Peptide Nanoparticles / Klaus Langer5.8： |
| Starting Materials for the Preparation of Nanoparticles / 6.1： |
| Preparation Methods / 6.3： |
| Nanoparticle Preparation by Emulsion Techniques / 6.3.1： |
| Emulsion Technique for the Preparation of Albumin-based Microspheres and Nanoparticles / 6.3.1.1： |
| Emulsion Technique for the Preparation of Gelatin-based Microspheres and Nanoparticles / 6.3.1.2： |
| Emulsion Technique for the Preparation of Casein-based Microspheres and Nanoparticles / 6.3.1.3： |
| Nanoparticle Preparation by Coacervation / 6.3.2： |
| Complex Coacervation Techniques for the Preparation of Nanoparticles / 6.3.2.1： |
| Simple Coacervation (Desolvation) Techniques for the Preparation of Nanoparticles / 6.3.2.2： |
| Basic Characterization Techniques for Peptide Nanoparticles / 6.4： |
| Drug Targeting with Nanoparticles / 6.5： |
| Passive Drug Targeting with Particle Systems / 6.5.1： |
| Active Drug Targeting with Particle Systems / 6.5.2： |
| Surface Modifications of Protein-based Nanoparticles / 6.5.3： |
| Surface Modification by Different Hydrophilic Compounds / 6.5.4： |
| Surface Modification by Polyethylene Glycol (PEG) Derivatives / 6.5.5： |
| Surface Modification by Drug-targeting Ligands / 6.5.6： |
| Different Surface Modification Strategies / 6.5.7： |
| Applications as Drug Carriers and for Diagnostic Purposes / 6.6： |
| Protein-based Nanoparticles in Gene Therapy / 6.6.1： |
| Parenteral Application Route / 6.6.2： |
| Preclinical Studies with Protein-based Particles / 6.6.2.1： |
| Clinical Studies with Protein-based Particles / 6.6.2.2： |
| Topical Application of Protein-based Particles / 6.6.3： |
| Peroral Application of Protein-based Particles / 6.6.4： |
| Immunological Reactions with Protein-based Microspheres / 6.7： |
| Albumin Nanoparticles / Socorro Espuelas6.8： |
| Serum Albumin / 7.1： |
| Preparation of Albumin Nanoparticles / 7.3： |
| "Conventional" Albumin Nanoparticles / 7.3.1： |
| Preparation of Albumin Nanoparticles by Desolvation or Coacervation / 7.3.1.1： |
| Preparation of Albumin Nanoparticles by Emulsification / 7.3.1.2： |
| Other Techniques to Prepare Albumin Nanoparticles / 7.3.1.3： |
| Surface-modified Albumin Nanoparticles / 7.3.2： |
| Drug Encapsulation in Albumin Nanoparticles / 7.3.3： |
| Biodistribution of Albumin Nanoparticles / 7.4： |
| Pharmaceutical Applications / 7.5： |
| Albumin Nanoparticles for Diagnostic Purposes / 7.5.1： |
| Radiopharmaceuticals / 7.5.1.1： |
| Echo-contrast Agents / 7.5.1.2： |
| Albumin Nanoparticles as Carriers for Oligonucleotides and DNA / 7.5.2： |
| Albumin Nanoparticles in the Treatment of Cancer / 7.5.3： |
| Fluorouracil and Methotrexate Delivery / 7.5.3.1： |
| Paclitaxel Delivery / 7.5.3.2： |
| Albumin Nanoparticles in Suicide Gene Therapy / 7.5.3.3： |
| Magnetic Albumin Nanoparticles / 7.5.4： |
| Albumin Nanoparticles for Ocular Drug Delivery / 7.5.5： |
| Topical Drug Delivery / 7.5.5.1： |
| Intravitreal Drug Delivery / 7.5.5.2： |
| Nanoscale Patterning of S-Layer Proteins as a Natural Self-assembly System / Margit Sara ; D. Pum ; C. Huber ; N. Ilk ; M. Pleschberger ; U. B. Sleytr7.6： |
| General Properties of S-Layers / 8.1： |
| Structure, Isolation, Self-Assembly and Recrystallization / 8.2.1： |
| Chemistry and Molecular Biology / 8.2.2： |
| S-Layers as Carbohydrate-binding Proteins / 8.2.3： |
| Nanoscale Patterning of S-Layer Proteins / 8.3： |
| Properties of S-Layer Proteins Relevant for Nanoscale Patterning / 8.3.1： |
| Immobilization of Functionalities by Chemical Methods / 8.3.2： |
| Patterning by Genetic Approaches / 8.3.3： |
| The S-Layer Proteins SbsA, SbsB and SbsC / 8.3.3.1： |
| S-Layer Fusion Proteins / 8.3.3.2： |
| Spatial Control over S-Layer Reassembly / 8.4： |
| S-Layers as Templates for the Formation of Regularly Arranged Nanoparticles / 8.5： |
| Binding of Molecules and Nanoparticles to Functional Domains / 8.5.1： |
| In Situ Synthesis of Nanoparticles on S-Layers / 8.5.2： |
| Conclusions and Outlook / 8.6： |
| Pharmaceutically Important Nanomaterials / III： |
| Methods of Preparation of Drug Nanoparticles / Jonghwi Lee ; Gio-Bin Lim ; Hesson Chung9： |
| Structures of Drug Nanoparticles / 9.1： |
| Thermodynamic Approaches / 9.3： |
| Lipid-based Pharmaceutical Nanoparticles / 9.3.1： |
| What is a Lipid? / 9.3.2： |
| Liquid Crystalline Phases of Hydrated Lipids with Planar and Curved Interfaces / 9.3.3： |
| Oil-in-water-type Lipid Emulsion / 9.3.4： |
| Liposomes / 9.3.5： |
| Cubosomes and Hexosomes / 9.3.6： |
| Other Lipid-based Pharmaceutical Nanoparticles / 9.3.7： |
| Mechanical Approaches / 9.4： |
| Types of Processing / 9.4.1： |
| Characteristics of Wet Comminution / 9.4.2： |
| Drying of Liquid Nanodispersions / 9.4.3： |
| SCF Approaches / 9.5： |
| SCF Characteristics / 9.5.1： |
| Classification of SCF Particle Formation Processes / 9.5.2： |
| RESS / 9.5.3： |
| SAS / 9.5.4： |
| SEDS / 9.5.5： |
| Electrostatic Approaches / 9.6： |
| Electrical Potential and Interfaces / 9.6.1： |
| Electrospraying / 9.6.2： |
| Production of Biofunctionalized Solid Lipid Nanoparticles for Site-specific Drug Delivery / Rainer H. Muller ; Eliana B. Souto ; Torsten Goppert ; Sven Gohla10： |
| Concept of Differential Adsorption / 10.1： |
| Production of SLN / 10.3： |
| Functionalization by Surface Modification / 10.4： |
| Conclusions / 10.5： |
| Biocompatible Nanoparticulate Systems for Tumor Diagnosis and Therapy / Mostafa Sadoqi ; Sunil Kumar ; Cesar Lau-Cam ; Vishal Saxena11： |
| Nanoscale Particulate Systems and their Building Blocks/Components / 11.1： |
| Dendrimers / 11.2.1： |
| Buckyballs and Buckytubes / 11.2.2： |
| Quantum Dots / 11.2.3： |
| Polymeric Micelles / 11.2.4： |
| Biodegradable Nanoparticles / 11.2.5： |
| Preparation of Nanoparticles / 11.3.1： |
| Biodegradable Optical Nanoparticles / 11.4： |
| Optical Nanoparticles as a Potential Technology for Tumor Diagnosis / 11.4.1： |
| Optical Nanoparticles as a Potential Technology for Tumor Treatment / 11.4.2： |
| Optical Imaging and PDT / 11.5： |
| Optical Imaging / 11.5.1： |
| Fluorescence-based Optical Imaging / 11.5.1.1： |
| NIR Fluorescence Imaging / 11.5.1.2： |
| NIR Dyes for Fluorescence Imaging / 11.5.1.3： |
| PDT / 11.5.2： |
| Basis of PDT / 11.5.2.1： |
| Photosensitizers for PDT / 11.5.2.2： |
| ICG: An Ideal Photoactive Agent for Tumor Diagnosis and Treatment / 11.5.3： |
| Clinical Uses of ICG / 11.5.3.1： |
| Structure and Physicochemical Properties of ICG / 11.5.3.2： |
| Binding Properties of ICG / 11.5.3.3： |
| Metabolism, Excretion and Pharmacokinetics of ICG / 11.5.3.4： |
| Toxicity of ICG / 11.5.3.5： |
| Tumor Imaging with ICG / 11.5.3.6： |
| PDT with ICG / 11.5.3.7： |
| Limitations of ICG for Tumor Diagnosis and Treatment / 11.5.3.8： |
| Recent Approaches for Improving the Blood Circulation Time and Uptake of ICG by Tumors / 11.5.3.9： |
| Recent Approaches for ICG Stabilization In Vitro / 11.5.3.10： |
| PLGA-based Nanoparticulate Delivery System for ICG / 11.6： |
| Rationale of Using a PLGA-based Nanoparticulate Delivery System for ICG / 11.6.1： |
| In Vivo Pharmacokinetics of ICG Solutions and Nanoparticles / 11.6.2： |
| Conclusions and Future Work / 11.7： |
| Nanoparticles for Crossing Biological Membranes / R. Pawar ; A. Avramoff ; A. J. Domb12： |
| Cell Membranes / 12.1： |
| Functions of Biological Membranes / 12.2.1： |
| Kinetic and Thermodynamic Aspects of Biological Membranes / 12.2.2： |
| Problems of Drugs Crossing through Biological Membranes / 12.3： |
| Through the Skin / 12.3.1： |
| Mechanical Irritation of Skin / 12.3.1.1： |
| Low-voltage Electroporation of the Skin / 12.3.1.2： |
| Through the BBB / 12.3.2： |
| Small Drugs / 12.3.2.1： |
| Limitations of Small Drugs / 12.3.2.1.1： |
| Peptide Drug Delivery via SynB Vectors / 12.3.2.2： |
| GI Barrier / 12.3.3： |
| Intestinal Translocation and Disease / 12.3.3.1： |
| Nanoparticulate Drug Delivery / 12.4： |
| Skin |
| Skin as Semipermeable Nanoporous Barrier / 12.4.1.1： |
| Hydrophilic Pathway through the Skin Barrier / 12.4.1.2： |
| Solid-Lipid Nanoparticles (SLN) Skin Delivery / 12.4.2： |
| Chemical Stability of SLN / 12.4.2.1： |
| In Vitro Occlusion of SLN / 12.4.2.2： |
| In Vivo SLN: Occlusion, Elasticity and Wrinkles / 12.4.2.3： |
| Active Compound Penetration into the Skin / 12.4.2.4： |
| Controlled Release of Cosmetic Compounds / 12.4.2.5： |
| Novel UV Sunscreen System Using SLN / 12.4.2.6： |
| Polymer-based Nanoparticulate Delivery to the Skin / 12.4.3： |
| Subcutaneous Nanoparticulate Antiepileptic Drug Delivery / 12.4.4： |
| Nanoparticulate Anticancer Drug Delivery / 12.4.5： |
| Paclitaxel / 12.4.5.1： |
| Doxorubicin / 12.4.5.2： |
| 5-Fluorouracil (5-FU) / 12.4.5.3： |
| Antineoplastic Agents / 12.4.5.4： |
| Gene Delivery / 12.4.5.5： |
| Breast Cancer / 12.4.5.6： |
| Nanofibers Composed of Nonbiodegradable Polymer / 12.4.6： |
| Electrostatic Spinning / 12.4.6.1： |
| Scanning Electron Microscopy / 12.4.6.2： |
| Differential Scanning Calorimetry (DSC) / 12.4.6.3： |
| Nanoparticulate Delivery to the BBB / 12.5： |
| Peptide Delivery to the BBB / 12.5.1： |
| Peptide Conjugation through a Disulfide Bond / 12.5.1.1： |
| Biodegradable Polymer Based Nanoparticulate Delivery to BBB / 12.5.2： |
| Nanoparticulate Gene Delivery to the BBB / 12.5.3： |
| Mechanism of Nanoparticulate Drug Delivery to the BBB / 12.5.4： |
| Nanoparticulate Thiamine-coated Delivery to the BBB / 12.5.5： |
| Nanoparticle Optics and Living Cell Imaging / 12.5.6： |
| Oral Nanoparticulate Delivery / 12.6： |
| Lectin-conjugated Nanoparticulate Oral Delivery / 12.6.1： |
| Oral Peptide Nanoparticulate-based Delivery / 12.6.2： |
| Polymer-Based Oral Peptide Nanoparticulate Delivery / 12.6.3： |
| Polyacrylamide Nanospheres / 12.6.3.1： |
| Poly(alkyl cyanoacrylate) PACA Nanocapsules / 12.6.3.2： |
| Derivatized Amino Acid Microspheres / 12.6.3.3： |
| Lymphatic Oral Nanoparticulate Delivery / 12.6.4： |
| Oral Nanosuspension Delivery / 12.6.5： |
| Mucoadhesion of Nanoparticles after Oral Administration / 12.6.6： |
| Protein Nanoparticulate Oral Delivery / 12.6.7： |
| Index |
図書
